8-K 1 form8k.htm NANOVIRICIDES 8-K 5-16-2007 Nanoviricides 8-K 5-16-2007
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
 

Date of report (Date of earliest event reported)
May 16, 2007
 
 
NANOVIRICIDES, INC.
(Exact Name of Registrant as Specified in Its Charter)
 

Nevada
  
000-1379006
  
76-0674577
(State or Other Jurisdiction of Incorporation)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)

135 Wood Street, Suite 205
  
06516
West Haven, Connecticut
    
(Address of Principal Executive Offices)
  
(Zip Code)
 
(203) 937-6137
(Registrant's Telephone Number, Including Area Code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Item 5.02.
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
 
On May 16 2007, Leo Ehrlich resigned as the Registrant’s Director and Chief Financial Officer. Dr. Eugene Seymour, the Registrant’s Chief Executive Officer was appointed to serve as Interim Chief Financial Officer of the Registrant.
 
Eugene Seymour, MD, MPH, age 65, has been Chief Executive Officer (CEO) and a director of the Registrant since June 1, 2005. From 1996 until May 2005 he has been a private investor and has held no corporate positions. During this period he formed a non-profit foundation which funded both testing and training programs for health workers in Asia and Africa. He was a consultant to the UN Global Program on AIDS and was sent to several countries, (Lithuania, Latvia, Estonia and Russia) to interact with local physicians and assist them in setting up testing programs. Dr. Seymour obtained a Master's degree in the Epidemiology of Infectious Diseases at UCLA in addition to his medical degree. He began clinical practice in Internal Medicine and joined the UCLA Medical School faculty. Dr. Seymour served in the Medical Corps of US Army Reserve during the Vietnam era and attained the rank of Major. In 1986, he was requested by the US government to establish a testing laboratory and run a large-scale surveillance program for HIV prevalence in the Hispanic population in Los Angeles. His laboratory ended up testing over 50,000 people. In 1989, Dr. Seymour founded StatSure Diagnostic Systems, Inc. (SDS) (formerly Saliva Diagnostic Systems, Inc.), developed the rapid HIV antibody blood test (Hema-Strip) and took the company public in 1993 as CEO and President. Dr. Seymour holds 8 issued patents.


SIGNATURES
 
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.

 
NANOVIRICIDES, INC.
  
     
       
Date: May 22,2007
By:  
/s/ Dr. Eugene Seymour
  
 
Dr. Eugene Seymour
  
  Chief Executive Officer